MAPT and Alzheimer disease: Notably, plasma pTau217 level may not only predict brain Aβ and tau status but also reflect the topographic extent and magnitude of tau aggregation across the clinical AD spectrum, enabling the discrimination of individuals at intermediate/advanced vs. early AD-stages (8).